Marco Piva

2.1k total citations · 1 hit paper
13 papers, 1.1k citations indexed

About

Marco Piva is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Marco Piva has authored 13 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 8 papers in Oncology and 3 papers in Cancer Research. Recurrent topics in Marco Piva's work include Melanoma and MAPK Pathways (4 papers), Cancer Cells and Metastasis (3 papers) and CAR-T cell therapy research (2 papers). Marco Piva is often cited by papers focused on Melanoma and MAPK Pathways (4 papers), Cancer Cells and Metastasis (3 papers) and CAR-T cell therapy research (2 papers). Marco Piva collaborates with scholars based in United States, Spain and United Kingdom. Marco Piva's co-authors include Gatien Moriceau, Roger S. Lo, Aayoung Hong, Willy Hugo, Lu Sun, María dM Vivanco, Bruno M. Simões, Xiangju Kong, Douglas B. Johnson and Jeffrey A. Sosman and has published in prestigious journals such as Cell, PLoS ONE and Analytical Chemistry.

In The Last Decade

Marco Piva

11 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

2015 412 citations Willy Hugo, Hubing Shi et al. Cell profile →

Peers

Countries citing papers authored by Marco Piva

Since Specialization

Citations

This map shows the geographic impact of Marco Piva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marco Piva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marco Piva more than expected).

Fields of papers citing papers by Marco Piva

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marco Piva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marco Piva. The network helps show where Marco Piva may publish in the future.

Co-authorship network of co-authors of Marco Piva

This figure shows the co-authorship network connecting the top 25 collaborators of Marco Piva. A scholar is included among the top collaborators of Marco Piva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marco Piva. Marco Piva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Enhancing PD-L1 Degradation by ITCH during MAPK Inhibitor Therapy Suppresses Acquired Resistance 2022 ·Cancer Discovery ·Zhentao Yang, (unknown), Sixue Liu, Weixian Deng, Shirley H. Lomeli, Gatien Moriceau, James A. Wohlschlegel, Marco Piva, Roger S. Lo	32
2	The Combined Use of Tocilizumab and Hemoadsorption in a Patient with SARS-COV-2-19-Associated Pneumonia: A Case Report 2020 ·The Nephron journals/Nephron journals ·Giorgio Berlot, (unknown), Erik Roman‐Pognuz, (unknown), (unknown), (unknown), Marco Piva, (unknown), (unknown), Francesco Bianco, (unknown), Paola Tomietto, Tommaso Trenti	16
3	Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma 2020 ·UNC Libraries ·Willy Hugo, Gatien Moriceau, Robert Damoiseaux, Roger S. Lo, (unknown), Aayoung Hong, Sheri L. Holmen, Shirley H. Lomeli, Norman E. Sharpless, Marco Piva	0
4	Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP 2018 ·Clinical Cancer Research ·(unknown), Andreia Silva, Tim Robinson, Angélica Santiago-Gómez, Bruno M. Simões, Michael W. Becker, Iduna Fichtner, Ladislav Anděra, (unknown), Christine M. Morris, Peter Barrett‐Lee, Fouad Alchami, Marco Piva, María dM Vivanco, Robert B. Clarke, Julia M.W. Gee, Richard Clarkson	42
5	High-Speed Live-Cell Interferometry: A New Method for Quantifying Tumor Drug Resistance and Heterogeneity 2018 ·Analytical Chemistry ·Dian Huang, (unknown), (unknown), (unknown), (unknown), Marco Piva, Gatien Moriceau, Thomas A. Zangle, Roger S. Lo, Michael A. Teitell, Jason Reed	32
6	Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation 2017 ·Cancer Discovery ·Chunying Song, Marco Piva, Lu Sun, Aayoung Hong, Gatien Moriceau, Xiangju Kong, Hong Zhang, Shirley H. Lomeli, Jin Qian, Clarissa C. Yu, Robert Damoiseaux, Mark C. Kelley, (unknown), Philip O. Scumpia, Jeffrey A. Sosman, Douglas B. Johnson, Antoni Ribas, Willy Hugo, Roger S. Lo	109
7	Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma 2017 ·Cancer Discovery ·Aayoung Hong, Gatien Moriceau, Lu Sun, Shirley H. Lomeli, Marco Piva, Robert Damoiseaux, Sheri L. Holmen, Norman E. Sharpless, Willy Hugo, Roger S. Lo	72
8	Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance breakdown → 2015 ·Cell ·Willy Hugo, Hubing Shi, Lu Sun, Marco Piva, Chunying Song, Xiangju Kong, Gatien Moriceau, Aayoung Hong, Kimberly B. Dahlman, Douglas B. Johnson, Jeffrey A. Sosman, Antoni Ribas, Roger S. Lo	412
9	Human Mammospheres Secrete Hormone-Regulated Active Extracellular Vesicles 2014 ·PLoS ONE ·Esperanza González, Marco Piva, Eva Rodríguez‐Suárez, David Gil‐Carton, Félix Royo, Félix Elortza, Juan Manuel Falcón‐Pérez, María dM Vivanco	13
10	Respuesta hormonal de las células madre de mama y resistencia a tamoxifeno 2014 ·Revista de Senología y Patología Mamaria ·Giacomo Domenici, Miriam Rábano, Marco Piva, Oihana Iriondo, Ignacio Zabalza, José Antonio López-Ruiz, María dM Vivanco	0
11	Sox2 promotes tamoxifen resistance in breast cancer cells 2013 ·EMBO Molecular Medicine ·Marco Piva, Giacomo Domenici, Oihana Iriondo, Miriam Rábano, Bruno M. Simões, Valentine Comaills, (unknown), José Antonio López-Ruiz, Ignacio Zabalza, Robert Kypta, María dM Vivanco	271
12	Effects of estrogen on the proportion of stem cells in the breast 2010 ·Breast Cancer Research and Treatment ·Bruno M. Simões, Marco Piva, Oihana Iriondo, Valentine Comaills, José Antonio López-Ruiz, Iñaki Zabalza, (unknown), (unknown), María dM Vivanco	96
13	Continuous renal replacement therapies in sepsis: Where is the evidence? 2006 ·Current Anaesthesia and Critical Care ·Giorgio Berlot, Marco Piva, Umberto Lucangelo, Marino Viviani, Gabriele Sganga	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact